Redeye states that the Q4 report was weaker than expected, especially regarding projects being delay...
Redeye comments on GiG’s Q4-results where topline came in stronger than expected while EBITDA was so...
Med en nyligen presenterad Q4-rapport anser vi att ChromoGenics fortsätter röra sig i rätt riktning ...
Kollect on Demand publicerade idag den 14 februari 2021 sin delårsrapport för fjärde kvartalet 2021.
Vaisala reports its Q4 result on Friday. In Q4, we expect revenue growth to scale till bottom rows a...
Stark lönsamhet och trading update Omsättningen i Q4 uppgick till EUR 98,2m vilket var i linje med v...
Rottneros annonserar joint venture med Arctic Paper i Polen Rottneros och Arctic Paper har beslutat ...
Accelererande organiskt tillväxt... Efterfrågan ökade tydligt för merparten av Midways bolag i Q4.
Redeye retains its positive view on Sdiptech following a slightly stronger Q4 report than expected.
Redeye retains its positive view on Bredband2 following a Q4 report largely in line with our forecas...
Raute’s Q4 report didn’t provide that many news as recent profitability challenges are familiar.
Mangold uppdaterar läkemedelsutvecklaren Double Bond Pharma (DBP).
Cibus will report its Q4 results on 24 February. We expect net operating income (NOI) of EUR 20.
EAB reported H2 comparable operating income of EUR 11.
Q4 was clearly hit by Covid-19, but we expect things to improve over the coming quarters (although Q...
Redeye comments on today’s updated schedule for Orphazyme’s planned NDA resubmission with arimoclomo...
Redeye comments on GiG’s extended contract with Betsson which now runs to Q4 25 which lowers risk an...
Redeye is encouraged to see another surprisingly strong quarter with sales beating our expectations ...
Redeye states that the partnership with MaxLinear further strengthens Sivers’ footprint through its ...
Redeye comments on Alligator Bioscience’s end-of-year report.
